Collectively called ‘checkpoint inhibitors’ (CPI), the two main classes targeting CTLA4 and the PD1/PD-L1 axis were broadly evaluated for their role in melanoma treatment, being the first disease to receive approval for non resectable metastatic disease[3]. Here, CTLA4 is linked to melanoma.